|Articles|March 18, 2021

European Union Drug Regulator Reassures Safety of AstraZeneca Vaccine

Author(s)Killian Meara

No causative link has been established between the shot and blood clots or severe bleeding.

On Thursday, the drug regulator of the European Union stated that the AstraZeneca COVID-19 vaccine is both safe and effective for use in the population. Officials hope that this reassurance will alleviate the growing concern around the vaccine, due to findings that the shot may lead to potential rare side effects.

Anxiety has grown over the vaccine because of cases of blood clots and lowered levels of blood platelets, spurring many nations within the EU to stop its administration. Over a dozen countries so far have paused the use of AstraZeneca, including Italy, Spain, France, Denmark, and Norway.

The move has been touted as a comfort strategy, ensuring that the public knows governments are taking all concerns seriously.

“In extensive vaccination campaigns, it is routine for countries to signal potential adverse events following immunization,” the World Health Organization (WHO) announced on Wednesday. “This does not necessarily mean that the events are linked to vaccination itself, but it is good practice to investigate them. It also shows that the surveillance system works and that effective controls are in place.”

The brief pause in the use of the vaccine comes at a time when Europe as a whole is struggling to contain a new wave of infections, threatening to roll back any progress that the union has made so far.

In Poland, more people are now on ventilators than at any other time during the pandemic, and Italy has once again reinstated lockdowns aiming to limit any outbreaks. In Paris, public hospitals are sounding alarms about the increasingly dire situation, stating that they are struggling to find enough beds in intensive care units.

Suspending the use of the AstraZeneca vaccine could very literally cost many lives.

However, with the reassurance from the drug regulator, many countries have said that they will likely restart its use and add the vaccine back into its arsenal.


Related to this article

Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.